Title: Cardiac Myxomas - symptomology, investigations and surgical treatment

Abstract:

From  May   2005  to  March   2021  , 50  patients  of  primary  or  recurrent  intracardiac  myxoma underwent  surgical  excision  at  our  institute.Their  age  ranged  from  25  years  to  55  years.Out  of  which  20  males  and  30  females.Commonest  presenting  symptoms  are  dyspnea  and  palpitation.35  Left  atrial,13  Right  atrial , one  right  ventricular  and  one  left  ventricular  myxoma.The diagnosis  was  doen  by  transthoracic  and  transesophageal  echocardiography.The    complete  wide  excision  with  margin   of  3-5 mm   normal surrounding   tissue  was  the  main  principle  of surgery.Right   atriotomy,right  ventricular  and  left ventricular   surgical  approach  was  used.Post  operative  echocardiogram  was  done  in  all  patients  before  discharge.Maximal   followup   of  five  years   and  minimum  followup  of  6  months  was  done  after  surgery.

Biography:

Dr. Suraj Wasudeo Nagre is an dedicated cardiovascular and thoracic surgeon working as Associate Professor CVTS at Grant Medical College, Mumbai, Maharashtra. After passing MBBS from Nagpur, he got MS General surgery, Jamnagar through all india enetrance

He has done his M Ch CVTS from prestigious institute Seth G S Medical college (KEM) in 2012. Also passed DNB CVTS in 2014. He has extensive clinical research and educational background in the field of congenital as well adult cardiac, vascular and thoracic surgery. His special interest lies in valvular and vascular surgeries.He is Fellow and life member of the Indian association of cardiothoracic surgeons (IACTS-FIACS), Vascular society of India (VSI), Society of minimal invasive cardiovascular and thoracic surgery (SMICTS) and Asian society of cardiovascular and thoracic surgery (ASCVTS). He has been working in government institute for the sake of poor patients refusing high salaried jobs since more than eight years.

Title: A potential Approach to treat and Prevent Severe Lung Injury Due to Novel Coronavirus (COVID-19) Infection by Blocking TGF1 and MMP-9

Abstract:

Individual infected with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), though the clinical presentation ranges from asymptomatic to mild flu-like symptoms, a significant minority develop severe lung injury with pneumonia, acute respiratory distress syndrome (ARDS) , respiratory failure, systemic inflammation, and multiorgan failure, which leading to considerable morbidity and mortality in the majority of the elderly patients with previous cardiovascular and chronic pulmonary inflammation comorbidities are particularly susceptible to these severe clinical manifestations with coronavirus disease 2019 (COVID-19). Recent clinical and biochemical evidence showing an increase in the levels of Matrix metalloproteinase-9 (MMP-9) in COVID-19 patients. MMP-9 is a matrix-degrading enzyme implicated in many biological processes, including inflammation; MMP-9 has been reported to activate latent transforming growth factor (TGF)-β to its active form and to induce TGF-β production in epithelial cells. TGF-β1 is believed to be a critical mediator of pathologic, fibrotic, and remodeling responses in the lung and other organs, and these responses are believed to be mediated by the ability of TGF-β1 to stimulate fibrogenic and apoptotic “injury” pathways, these observations have led to the suggestion that MMP-9 plays an important role in the tissue remodeling that characterizes many lung diseases.

Biography:

Now I am serving as a Dean of Faculty of Medical and Health Sciences at ECT. I had an overall academic strategic responsibility for establishing many health and medical institutes in Middle East countries. I have possessed a strong teaching background. I have also extensive experience as a researcher in pharmacology, biochemistry, toxicology and clinical pharmacology through the supervision of students and junior pharmacists & other medical-related sciences and researchers